title: Multicenter trial of fleroxacin versus ceftriaxone in the treatment of uncomplicated gonorrhea.
abstract: In a multicenter, randomized, open, comparative trial, patients with uncomplicated gonorrhea were treated with 400 mg of oral fleroxacin or 250 mg of intramuscular ceftriaxone. A total of 458 men and 447 women were enrolled. Of these, 312 men (68%) and 245 women (55%) were evaluable for efficacy. The treatment groups were demographically similar. Among evaluable men, fleroxacin eradicated 154 of 155 (99%; 95% confidence interval [CI]: 98.1-100%) urethral and 2 of 2 pharyngeal infections, while ceftriaxone eradicated 156 of 156 (95% CI: 99.4-100%) urethral and 5 of 5 pharyngeal infections. Among evaluable women, fleroxacin eradicated 127 of 128 (99%; 95% CI: 97.7-100%) cervical, 20 of 20 anorectal, 16 of 16 urethral, and 7 of 7 pharyngeal infections, while ceftriaxone eradicated 108 of 108 (95% CI: 99.1-100%) cervical, 24 of 24 anorectal, 25 of 25 urethral, and 9 of 9 pharyngeal infections. Adverse events were reported by 68 (16%) of 426 subjects in the fleroxacin group and 20 (5%) of 380 in the ceftriaxone group (p < 0.0001). The most common adverse events reported by the patients who received fleroxacin were nausea (5%), headache (3%), and vaginitis (3%). One patient had severe vomiting, 19 participants had adverse reactions classified as moderate, and 48 patients had mild adverse reactions. Fleroxacin was highly effective in the treatment of uncomplicated gonorrhea and represents an oral alternative to ceftriaxone. Adverse events were more common with fleroxacin than with ceftriaxone.
authors.affiliation: State University of New York, Health Science Center, Brooklyn 11203.
authors.forename: B L
authors.initials: BL
authors.lastname: Smith
authors.forename: W J
authors.initials: WJ
authors.lastname: Mogabgab
authors.forename: Z A
authors.initials: ZA
authors.lastname: Dalu
authors.forename: R B
authors.initials: RB
authors.lastname: Jones
authors.forename: J M
authors.initials: JM
authors.lastname: Douglas
authors.forename: H H
authors.initials: HH
authors.lastname: Handsfield
authors.forename: E W
authors.initials: EW
authors.lastname: Hook
authors.forename: B L
authors.initials: BL
authors.lastname: Viner
authors.forename: J W
authors.initials: JW
authors.lastname: Shands
authors.forename: W M
authors.initials: WM
authors.lastname: McCormack
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002443:Ceftriaxone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002690:Chlamydia Infections / Q000188:drug therapy; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D005260:Female; D016576:Fleroxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006069:Gonorrhea / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009344:Neisseria gonorrhoeae / Q000302:isolation & purification
chemical_list: D002443:Ceftriaxone; D016576:Fleroxacin